BIO-RAD LABORATORIES executive Evran Sedat exercised Options for 1,891 shares at $0 per share across two transactions, leaving 1,728 derivative securities. For investors, the report separates common-share ownership from derivative-security holdings, while a separate award left 4,026 derivative securities in Sedat’s reported holdings.

Key Highlights

  • Evran Sedat received an award of 4,026 derivative securities on September 4.
  • The award represented about 100.0% of Sedat’s resulting derivative-securities holding.
  • Transactions coded F were completed at $386.11 per share, after which Sedat owned 3,603 shares.

BIO-RAD LABORATORIES, INC. (NYSE: BIO) executive Evran Sedat exercised options for 1,891 shares at $0 per share across two transactions between September 5 and September 6. Sedat serves as executive vice president of Global Supply Chain. The transactions left Sedat with 3,880 shares.

Share Transactions and Updated Ownership

The option exercises carried SEC transaction code M. Separate transactions coded F were completed at $386.11 per share, after which Sedat owned 3,603 shares. The reported activity occurred between September 5 and September 6.

Derivative Securities Held After Exercise

Sedat received 4,026 derivative securities on September 4 through a transaction coded A. That award represented about 100.0% of the resulting derivative-securities holding. Sedat then exercised options for 1,891 derivative securities at $0 per share across two transactions. Following those transactions, Sedat owned 1,728 derivative securities. Transaction code M denotes the exercise or conversion of a derivative security.